Independent clones in CLL show oligoclonality and early evolution patterns
The ASCO 2025 meeting highlights crucial advancements in breast cancer treatments, emphasizing new clinical trials and the role of PIK3CA mutations. Positive results show improved progression-free survival with innovative treatment combinations.
The discussion includes emerging oral agents and the necessity of ESR1 mutation testing.
New PROTAC agents targeting estrogen receptors are introduced, showcasing the collaborative efforts of healthcare professionals in advancing cancer research.
Independent clones in CLL show oligoclonality and early evolution patterns
Breast cancer survivorship
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
Understanding AL amyloidosis: Treatment and diagnosis
Advances in multiple myeloma treatment in the Philippines